keyword
MENU ▼
Read by QxMD icon Read
search

Tuberculosis, humira

keyword
https://www.readbyqxmd.com/read/30169904/comprehensive-long-term-safety-of-adalimumab-from-18-clinical-trials-in-adult-patients-with-moderate-to-severe-plaque-psoriasis
#1
C Leonardi, K Papp, B Strober, D Thaçi, R B Warren, S Tyring, D Arikan, M Karunaratne, W C Valdecantos
BACKGROUND: Adalimumab (Humira® , AbbVie Inc., North Chicago, IL, U.S.A.) is a fully human monoclonal antibody specific for tumour necrosis factor-α that is approved to treat adults with moderate-to-severe chronic plaque psoriasis. OBJECTIVES: To assess long-term safety for patients with psoriasis receiving adalimumab in clinical studies. METHODS: Adalimumab safety data from adults with psoriasis who received at least one adalimumab dose in 18 clinical trials were evaluated...
August 31, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/20419463/cerebral-tuberculoma-in-a-patient-receiving-anti-tnf-alpha-adalimumab-treatment
#2
Karen Lynch, Michael Farrell
We report a case of a cerebral tuberculoma in a 60-year-old woman with rheumatoid arthritis while receiving the anti-tumor necrosis factor alpha monoclonal antibody, adalimumab (Humira), for active disease. MR brain imaging for dyspraxia revealed a left parietal ring-enhancing lesion, which on resection was shown to be a necrotizing granuloma. There were no associated pulmonary lesions, and the patient was systemically well. Sputum and urine cultures were negative for tuberculosis. The patient was treated with anti-tuberculous medications and made an excellent recovery...
October 2010: Clinical Rheumatology
https://www.readbyqxmd.com/read/19801257/-severe-tularaemia-mimicking-glandular-tuberculosis-during-adalimumab-therapy
#3
M-P Konstantinou, S Abecassis-Cotta, L Valeyrie-Allanore, N Ortonne, M Maurin, J-C Roujeau, J Revuz, M Bagot
BACKGROUND: Tularaemia is an anthropozoonosis, transmitted by small mammals (hares) and arthropods (ticks, horseflies). The causative agent is Francisella tularensis, a facultatively intracellular Gram-negative bacillus. We report a case of tularaemia in its ulceroglandular form occurring during methotrexate and adalimumab treatment (Humira) for rheumatoid arthritis. PATIENTS AND METHODS: A 58-year-old man with a history of primary tuberculosis receiving adalimumab in combination with methotrexate for rheumatoid arthritis for almost 1 year consulted for a febrile inflammatory plaque on the left leg with a small central necrotic area...
October 2009: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/16439435/safety-analyses-of-adalimumab-humira-in-global-clinical-trials-and-us-postmarketing-surveillance-of-patients-with-rheumatoid-arthritis
#4
M H Schiff, G R Burmester, J D Kent, A L Pangan, H Kupper, S B Fitzpatrick, C Donovan
OBJECTIVE: To assess the safety of adalimumab in global clinical trials and postmarketing surveillance among patients with rheumatoid arthritis (RA). METHODS: Safety data for adalimumab treated patients from randomised controlled trials, open label extensions, and two phase IIIb open label trials were analysed. In addition, postmarketing spontaneous reports of adverse events in the United States were collected following Food and Drug Administration approval of adalimumab on 31 December 2002...
July 2006: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/16134723/therapy-of-ankylosing-spondylitis-part-ii-biological-therapies-in-the-spondyloarthritides
#5
REVIEW
J Braun, X Baraliakos, J Brandt, J Sieper
Therapeutic options for patients with active and severe spondylarthritis (SpA) have been fairly limited in the past decades. There is now accumulating evidence that biological therapy with agents directed against tumour necrosis factor-alpha (TNF-alpha) is highly efficacious in the spondyloarthritides, especially in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). The TNF blocking agents currently available, infliximab (Remicade), etanercept (Enbrel), and adalimumab (Humira), are approved for the treatment of rheumatoid arthritis (RA) in Europe and the USA...
May 2005: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/16011443/adalimumab-a-review-of-side-effects
#6
REVIEW
Noah Scheinfeld
Adalimumab (Humira) is a human monoclonal TNF-alpha antibody that blocks the effects of TNF-alpha. It is administered by subcutaneous injection. It has been approved alone or in combination with methotrexate for the treatment of rheumatoid arthritis in the EU and US. Approval for its use for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis is expected in the near future. Its side effect profile is favourable when compared with traditional systemic treatments for these diseases. It does not require laboratory monitoring...
July 2005: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/15335295/considerations-with-the-use-of-biological-therapy-in-the-treatment-of-rheumatoid-arthritis
#7
REVIEW
Roy M Fleischmann, Imran Iqbal, Richard L Stern
The treatment of rheumatoid arthritis (RA) has changed dramatically over the past 15 years with the realisation that earlier, aggressive therapy limits progression. There is evidence that biological response modifiers (BRMs), which target specific cytokines such as TNF-alpha and IL-1, are more effective than traditional disease-modifying antirheumatic drugs (DMARDs), especially in combination with methotrexate. Four therapies are approved for use in RA; three target TNF-alpha (etanercept [Enbrel, Amgen Inc...
September 2004: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/15295313/tuberculosis-associated-with-blocking-agents-against-tumor-necrosis-factor-alpha-california-2002-2003
#8
(no author information available yet)
The Food and Drug Administration (FDA) has determined that tuberculosis (TB) disease is a potential adverse reaction from treatment with the tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab (Remicade), etanercept (Enbrel), and adalimumab (Humira); the three products are labeled accordingly. These products work by blocking TNF-alpha, an inflammatory cytokine, and are approved for treating rheumatoid arthritis and other selected autoimmune diseases. TNF-alpha is associated with the immunology and pathophysiology of certain infectious diseases, notably TB; blocking TNF-alphacan allow TB disease to emerge from latent Mycobacterium tuberculosis infection...
August 6, 2004: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/15187239/biological-therapies-in-the-spondyloarthritides-the-current-state
#9
REVIEW
J Braun, J Sieper
Therapeutic options for patients suffering from the more severe spondyloarthritides (SpA) have been rather limited in the last decades. Evidence is now accumulating that anti-tumour necrosis factor (TNF) therapy is highly effective in SpA, especially in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Based on the data recently published concerning more than 1000 patients with AS and PsA, this treatment seems to be even more effective than in rheumatoid arthritis (RA). The anti-TNFalpha agents currently available, infliximab (Remicade), etanercept (Enbrel) and adalimumab (Humira), are approved for the treatment of RA in the USA and Europe...
September 2004: Rheumatology
https://www.readbyqxmd.com/read/15046527/adalimumab-a-review-of-its-use-in-rheumatoid-arthritis
#10
REVIEW
Lynne M Bang, Gillian M Keating
Adalimumab (Humira) is a recombinant, fully human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor (TNF)-alpha, thereby neutralizing the activity of the cytokine. Subcutaneous adalimumab has been investigated in well designed trials in patients with active rheumatoid arthritis despite treatment with disease-modifying antirheumatic drugs (DMARDs). Patients receiving adalimumab 40mg every other week in combination with methotrexate (Anti-TNF Research Study Program of the Monoclonal Antibody Adalimumab [ARMADA] and DE019 trials) or standard antirheumatic therapy (Safety Trial of Adalimumab in Rheumatoid Arthritis [STAR] trial) for 24-52 weeks had significantly higher American College of Rheumatology (ACR) 20, ACR50, and ACR70 response rates than patients receiving placebo plus methotrexate or standard antirheumatic therapy...
2004: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/12831346/novel-approaches-in-the-treatment-of-ankylosing-spondylitis-and-other-spondyloarthritides
#11
REVIEW
Juergen Braun, Désirée van der Heijde
The therapeutic options for patients suffering from severe forms of spondyloarthritis (SpA) have been rather limited in recent decades. There is now accumulating evidence that anti-TNF therapy is highly effective in SpA, especially in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Based on the data recently published on what is now several hundred AS and PsA patients, this treatment seems to be even more effective than the same therapy in rheumatoid arthritis (RA). The anti-TNF-alpha agents currently available, infliximab (Remicade); Centocor), etanercept (Enbrel); Amgen) and adalimumab (Humira; Abbott), are approved for the treatment of RA in the US; infliximab and etanercept are approved in Europe...
July 2003: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/12819466/biologic-therapies-in-the-spondyloarthritis-new-opportunities-new-challenges
#12
REVIEW
Juergen Braun, Jan Brandt, Joachim Listing, Martin Rudwaleit, Joachim Sieper
Therapeutic options for patients suffering from the more severe forms of spondyloarthritis have been rather limited in the last decades. There is now accumulating evidence that antitumor necrosis factor therapy is highly effective in spondyloarthritis, especially in ankylosing spondylitis and psoriatic arthritis. Based on the data recently published on more than 500 patients with ankylosing spondylitis and psoriatic arthritis, this treatment seems to be even more effective than in rheumatoid arthritis. The antitumor necrosis factor-alpha agents currently available, infliximab (Remicade), etanercept (Enbrel), and adalimumab (Humira), are approved for the treatment of rheumatoid arthritis in the United States and partly in Europe...
July 2003: Current Opinion in Rheumatology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"